Ambisome as first line treatment of a child with ALL associated with the relapse of leishmaniasis

Ambisome as first line treatment of a child with ALL associated with the relapse of leishmaniasis

Bibliographic Details
Main Authors:	D.B. Alia, R. Petrela, A. Godo, A. Barbullushi, P. Daja, A. Arapi, M. Xhafa
Format:	Article
Language:	English
Published:	Elsevier 2014-04-01
Series:	International Journal of Infectious Diseases
Online Access:	http://www.sciencedirect.com/science/article/pii/S1201971214010960

Similar Items

Effectiveness and safety of short course liposomal amphotericin B (AmBisome) as first line treatment for visceral leishmaniasis in Bangladesh.
by: Emiliano Lucero, et al.
Published: (2015-04-01)

Risk factors for visceral leishmaniasis relapse in immunocompetent patients following treatment with 20 mg/kg liposomal amphotericin B (Ambisome) in Bihar, India.
by: Sakib Burza, et al.
Published: (2014-01-01)

A randomized trial of AmBisome monotherapy and AmBisome and miltefosine combination to treat visceral leishmaniasis in HIV co-infected patients in Ethiopia.
by: Ermias Diro, et al.
Published: (2019-01-01)

Correction: Risk Factors for Visceral Leishmaniasis Relapse in Immunocompetent Patients following Treatment with 20 mg/kg Liposomal Amphotericin B (Ambisome) in Bihar, India
by: The Staff
Published: (2014-04-01)

Correction: Risk Factors for Visceral Leishmaniasis Relapse in Immunocompetent Patients following Treatment with 20 mg/kg Liposomal Amphotericin B (Ambisome) in Bihar, India.
Published: (2014-04-01)

Development of post-kala-azar dermal leishmaniasis in AmBisome treated visceral leishmaniasis: A possible challenge to elimination program in India
by: VNR Das, et al.
Published: (2013-01-01)

Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh.
by: Ridwanur Rahman, et al.
Published: (2017-05-01)

Post Kala-Azar dermal leishmaniasis following treatment with 20 mg/kg liposomal amphotericin B (Ambisome) for primary visceral leishmaniasis in Bihar, India.
by: Sakib Burza, et al.
Published: (2014-01-01)

Comparative efficacy, toxicity and biodistribution of the liposomal amphotericin B formulations Fungisome® and AmBisome® in murine cutaneous leishmaniasis
by: Gert-Jan Wijnant, et al.
Published: (2018-08-01)

Safety and efficacy of single dose versus multiple doses of AmBisome for treatment of visceral leishmaniasis in eastern Africa: a randomised trial.
by: Eltahir A G Khalil, et al.
Published: (2014-01-01)

Visceral leishmaniasis and HIV co-infection in Bihar, India: long-term effectiveness and treatment outcomes with liposomal amphotericin B (AmBisome).
by: Sakib Burza, et al.
Published: (2014-08-01)

Efficacy and Safety of AmBisome in Combination with Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized Trial.
by: Monique Wasunna, et al.
Published: (2016-09-01)

Combination therapy with liposomal amphotericin b (ambisome), n-methylglucamine antimoniate (glucantime), and pentamidine isethionate in a refractory visceral leishmaniasis case
by: Maria Antonia Ferreira Gomes, et al.

Hypokalaemia-induced rhabdomyolysis after treatment of post-Kala-azar dermal Leishmaniasis (PKDL) with high-dose AmBisome in Bangladesh-a case report.
by: Ulrika Marking, et al.
Published: (2014-06-01)

Five-year field results and long-term effectiveness of 20 mg/kg liposomal amphotericin B (Ambisome) for visceral leishmaniasis in Bihar, India.
by: Sakib Burza, et al.
Published: (2014-01-01)

Tissue-specific transcriptomic changes associated with AmBisome® treatment of BALB/c mice with experimental visceral leishmaniasis [version 1; peer review: 2 approved]
by: Sarah Forrester, et al.
Published: (2019-12-01)

Single-dose liposomal amphotericin B (AmBisome<sup>®</sup>) for the treatment of Visceral Leishmaniasis in East Africa: study protocol for a randomized controlled trial
by: Smith Peter G, et al.
Published: (2011-03-01)

Correction: Five-Year Field Results and Long-Term Effectiveness of 20 mg/kg Liposomal Amphotericin B (Ambisome) for Visceral Leishmaniasis in Bihar, India
by: The Staff
Published: (2014-04-01)

Correction: Five-Year Field Results and Long-Term Effectiveness of 20 mg/kg Liposomal Amphotericin B (Ambisome) for Visceral Leishmaniasis in Bihar, India.
Published: (2014-04-01)

The initial effectiveness of liposomal amphotericin B (AmBisome) and miltefosine combination for treatment of visceral leishmaniasis in HIV co-infected patients in Ethiopia: A retrospective cohort study.
by: Charles Abongomera, et al.
Published: (2018-05-01)

Mucosal relapse of visceral leishmaniasis in a child treated with anti-TNFα
by: E. Jeziorski, et al.
Published: (2015-04-01)

Parasitic loads in tissues of mice infected with Trypanosoma cruzi and treated with AmBisome.
by: Sabrina Cencig, et al.
Published: (2011-06-01)

The Viscoelastic Properties of the Fungal Cell Wall Allow Traffic of AmBisome as Intact Liposome Vesicles
by: Louise Walker, et al.
Published: (2018-02-01)

Miltefosine Rescue Treatment for Visceral Leishmaniasis Relapse Patient
by: Anup Bastola, et al.
Published: (2019-01-01)

An unusual relapsing case of skin leishmaniasis
by: E.M. Netto, et al.
Published: (1990-06-01)

An unusual relapsing case of skin leishmaniasis
by: E.M. Netto, et al.
Published: (1990-06-01)

AMBIsome Therapy Induction OptimisatioN (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority Trial
by: David S. Lawrence, et al.
Published: (2018-11-01)

Correction to: AMBIsome Therapy Induction OptimisatioN (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority Trial
by: David S. Lawrence, et al.
Published: (2019-01-01)

Relationship of Serum Antileishmanial Antibody With Development of Visceral Leishmaniasis, Post-kala-azar Dermal Leishmaniasis and Visceral Leishmaniasis Relapse
by: Dinesh Mondal, et al.
Published: (2019-10-01)

Visceral Leishmaniasis in HIV-Infected Patients: The Challenge of Relapse and Treatment Failure
by: Patrícia Cipriano, et al.
Published: (2017-06-01)

Peroral amphotericin B polymer nanoparticles lead to comparable or superior in vivo antifungal activity to that of intravenous Ambisome® or Fungizone™.
by: Jagdishbhai L Italia, et al.
Published: (2011-01-01)

Comparison of first-line therapies for relapsing-remitting multiple sclerosis
by: Yennam, Amulya
Published: (2021)

Relationship between treatment regimens for visceral leishmaniasis and development of post-kala-azar dermal leishmaniasis and visceral leishmaniasis relapse: A cohort study from Bangladesh.
by: Dinesh Mondal, et al.
Published: (2019-08-01)

Macrophage Activation Marker Neopterin: A Candidate Biomarker for Treatment Response and Relapse in Visceral Leishmaniasis
by: Anke E. Kip, et al.
Published: (2018-06-01)

Visceral leishmaniasis relapse in HIV patients--a role for myeloid-derived suppressor cells?
by: Rafael Van den Bergh, et al.
Published: (2014-09-01)

Predictors of relapse of visceral leishmaniasis in inner São Paulo State, Brazil
by: José Cláudio Simão, et al.
Published: (2020-06-01)

Long-term incidence of relapse and post-kala-azar dermal leishmaniasis after three different visceral leishmaniasis treatment regimens in Bihar, India.
by: Vishal Goyal, et al.
Published: (2020-07-01)

Visceral leishmaniasis and haemophagocytic syndrome in an Omani child
by: Khalfan Al Sineidi, et al.
Published: (2002-04-01)

Amphotericin B deoxycholate for relapse visceral leishmaniasis in Bangladesh: a cross-sectional study
by: Md Golam Hasnain, et al.
Published: (2018-12-01)

Predictors of visceral leishmaniasis relapse in HIV-infected patients: a systematic review.
by: Gláucia F Cota, et al.
Published: (2011-06-01)